xanax from india

ingredients in xanax

Important Safety Information Multaq is contraindicated in patients with NYHA Class IV heart failure or NYHA Class II-III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. In patients with new or worsening heart failure, the suspension or discontinuation of Multaq should be considered.S. xanax from india About dronedarone (Multaq) Multaq, discovered and developed by sanofi-aventis, is one of the major therapeutic innovations in patients with atrial fibrillation in the last twenty years.sanofi-aventis. xanax from india 5 million people in the United States and 4. The ANDROMEDA study, was terminated prematurely after enrolment of 627 of 1000 planned patients with congestive heart failure, in relation to excess mortality due to worsening heart failure in the dronedarone group [n=25 versus 12 (placebo), p=0. adipex danger

The patients enrolled in ANDROMEDA had relatively severe heart failure and had been hospitalized, or referred to a specialty heart failure clinic for worsening symptoms. "Sanofi-aventis is proud of its ability to bring innovative therapies to market and contribute to reducing the public health burden of atrial fibrillation. Multaq should not be coadministered with strong CYP 3A inhibitors or medicinal products that prolong the QT interval. Sanofi-aventis is listed in Paris and in New York . xanax from india In contrast, in ATHENA, all patients had a history of AF/AFL, and 71% of patients had no heart failure, 25% were NYHA class I or II, and only 4% were class III. xanax from india The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance. ambien scholarship

Multaq is an anti-arrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted. The FDA approval is based on five international, multi-center, randomized clinical trials involving nearly 6,300 patients. Patients were predominantly NYHA II and III (New York Heart Association classification) and only 25% had a history of AF/AFL at randomization. About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. xanax from india Such patients should not be given dronedarone. xanax from india 001) compared with placebo meeting the primary endpoint.